Evidence map›Paper›PMID 40090753›Full record

ReviewSeminars in radiation oncology2025

Radiation-Therapy Related Salivary Dysfunction.

Grace C Blitzer, Cristina Paz, Sara S McCoy, Randall J Kimple

Abstract readReview
In one paragraph

Review in Seminars in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Tempol Protects Against Radiation Injury in the Submandibular Gland Through the β-Catenin Signaling Pathway.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Grace C BlitzerDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.; University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Cristina PazDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Sara S McCoyUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI.; Department of Medicine, Division of Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Randall J KimpleDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.; University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI.. Electronic address: rkimple@humonc.wisc.edu.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
Project 3: Modulation of the head and neck tumor immune microenvironment by targeting the TAM family of receptorsP50CA278595 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI David J Beebe · 2022 to 2026
$12.5M
Intra-salivary gland autotransplantation of marrow mesenchymal stromal cells for treatment of radiation induced xerostomiaUH3DE030431 · NIDCR · UNIVERSITY OF WISCONSIN-MADISON · PI Jacques Galipeau, Randall J. Kimple · 2023 to 2026
$2.0M
Planning a phase I study of minor salivary gland derived autologous MSCs for prevention of long-term radiation induced xerostomiaR34DE033042 · NIDCR · UNIVERSITY OF WISCONSIN-MADISON · PI KIMPLE, RANDALL J., MCCOY, SARA · 2023 to 2024
$298k
Mesenchymal stromal cells for treatment of radiation-induced xerostomiaF31DE031180 · NIDCR · UNIVERSITY OF WISCONSIN-MADISON · PI PAZ, CRISTINA · 2022 to 2024
$112k
NCI NIH HHS P30 CA014520NCI NIH HHS P50 CA278595NIDCR NIH HHS F31 DE031180NIDCR NIH HHS R34 DE033042NIDCR NIH HHS UH3 DE030431
6 · The paper itself

Abstract

Radiation-induced xerostomia (RIX) is a common and debilitating side effect of head and neck cancer radiotherapy, significantly impacting patients' quality of life. This review comprehensively summarizes the current understanding of RIX, encompassing its clinical quantification, underlying pathophysiology, and established and emerging treatment modalities. We explore various objective and subjective measures used to quantify salivary flow and assess the severity of xerostomia in clinical settings. The pathophysiological mechanisms leading to RIX are elucidated, including radiation damage to salivary glands, alterations in saliva composition, and the role of inflammatory processes. Current treatment strategies, such as saliva substitutes and stimulants, are discussed alongside their limitations. Furthermore, we delve into novel investigational approaches, including gene therapy, stem cell transplantation, and pharmacologic interventions, offering promising avenues for future RIX management. This review provides clinicians and researchers with a comprehensive overview of RIX, highlighting the need for continued research to develop more effective preventative and therapeutic strategies to alleviate this burdensome condition.

Indexed as

Head and Neck NeoplasmsRadiation InjuriesRadiotherapySalivary GlandsXerostomiaHumansQuality of Life

Identifiers

PMID40090753
PMCPMC11911547

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.